Several drugmakers have been flirting with continuous process manufacturing, but none have fully engaged with the idea. GlaxoSmithKline has been working on the new technology for 5 or 6 years and is now ready to make a serious commitment to a method that requires radically smaller plants and, further, promises radically lower operating costs.  Click here to read more.